Sterling Pharma Solutions, a Dudley, UK-based CDMO of small-molecule active pharmaceutical ingredients (APIs) and intermediates, has acquired a small-molecule API manufacturing facility in Germantown, Wisconsin from Alcami, a CDMO of APIs and drug products.

The new facility will further bolster Sterling’s US presence and will provide additional capacity for customer API development and manufacturing projects. The Germantown facility has cGMP development, scale-up, and manufacturing capabilities, including plant-scale hydrogenation and cryogenic reactions. The acquisition follows recent investments by Sterling totaling $46 million, which includes a recent $1.5-million investment into the company’s facility in North Carolina.

The Germantown facility was the main API development and manufacturing facility for Alcami. In January (January 2020), it sold its preclinical and early-stage API facility in Weert, Netherlands to MercachemSyncom, a mid-sized European drug-discovery and development contract research organization.

The moves to sell its API facilities follows Alcami’s expansion of its sterile fill–finish capacity. In January (January 2020), it acquired TriPharm Services, a CDMO, which commissioned a new manufacturing center for sterile fill–finish services. Operational capabilities will continue to build across the next two years with the completion of Phase I of the manufacturing facility in the fourth quarter of 2020, which will bring the first two filling suites on line. Alcami’s acquisition of TriPharm followed a recently announced $17-million expansion of its sterile fill–finish facility in Charleston, South Carolina.

Source: Sterling Pharma Solutions and Alcami